Wellcome suffers as Zovirax lets down City
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Wellcome's share price fell 51p to 550p yesterday as the City looked askance at interim figures that failed to deliver hoped-for underlying growth in the drug company's main product, Zovirax.
Although total sales of the herpes treatment rose 10 per cent in constant currencies to pounds 418m - more than a third of Wellcome's turnover - a price hike in the US was a significant factor. American sales of Zovirax, which account for almost half the total, grew by an underlying 14 per cent but the increase was only 8 per cent excluding the price rise.
Sentiment was also affected by sales of Retrovir, the anti-HIV treatment, which fell 16 per cent to pounds 110m. Retrovir has suffered from the negative preliminary conclusions of the Anglo-French Concorde study about its effectiveness.
However, the trading statement concluded that publication of the full Concorde data - expected after Easter - should have little further impact on sales.
Group pre-tax profits before exceptionals were up 12 per cent to pounds 364m in the six months ended February; the headline pre-tax figure was pounds 358.1m. Sales of pounds 1bn were up 5 per cent.
The interim dividend rises 3.8p to 8.6p a share. This is partly because the company is changing to a December year-end, which means final dividends will be received in May/June instead of January. But Wellcome also intends to cut dividend cover from last year's 2.7 times earnings - the industry average is 2.2 times.
View from City Road, page 32
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments